Point72 Asset Management’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
Other funds holding TVRD
DGI
C
FCM
Point72 Asset Management's TVRD Position: Q4 2023 in Review
Point72 Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 3 shares — an estimated $195 sold.
Point72 Asset Management first reported a position in TVRD in Q2 2015 and held it in 12 quarters. The position peaked at $8.94M in Q4 2015. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.
- Point72 Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
- Point72 Asset Management sold 3 Tvardi Therapeutics shares in Q4 2023, an estimated $195.
- Point72 Asset Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 12 quarters.
- Point72 Asset Management's Tvardi Therapeutics position peaked at $8.94M in Q4 2015.
- 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.
Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.